Globe Newswire (Tue, 21-Apr 9:00 AM ET)
TipRanks (Tue, 21-Apr 6:16 AM ET)
Market Chameleon (Mon, 20-Apr 4:56 AM ET)
Globe Newswire (Mon, 20-Apr 8:35 AM ET)
Globe Newswire (Thu, 9-Apr 8:50 AM ET)
Globe Newswire (Mon, 6-Apr 8:45 AM ET)
Globe Newswire (Wed, 18-Mar 8:05 AM ET)
Akari Therapeutics Announces ADS Ratio Change
Globe Newswire (Tue, 17-Mar 4:30 PM ET)
Globe Newswire (Fri, 13-Mar 9:15 AM ET)
Globe Newswire (Thu, 26-Feb 9:10 AM ET)
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.
Akari Therapeutics PLC - American Depositary Shares trades on the NASDAQ stock market under the symbol AKTX.
As of April 24, 2026, AKTX stock price declined to $5.80 with 1,031 million shares trading.
AKTX has a beta of 2.26, meaning it tends to be more sensitive to market movements. AKTX has a correlation of 0.08 to the broad based SPY ETF.
AKTX has a market cap of $207.29 million. This is considered a Small Cap stock.
In the last 3 years, AKTX traded as high as $220.00 and as low as $3.25.
AKTX has underperformed the market in the last year with a return of -90.1%, while the SPY ETF gained +31.9%. In the last 3 month period, AKTX fell short of the market, returning -47.0%, while SPY returned +3.8%. However, in the most recent 2 weeks AKTX has outperformed the stock market by returning +51.4%, while SPY returned +5.1%.
AKTX support price is $5.31 and resistance is $6.69 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AKTX shares will trade within this expected range on the day.
